The primary molecular target structure in AML blasts is CD33, based on which the humanized anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin, as well as ineffective therapies of CD33- or CD123-based CAR-T cells, were developed [143,144]. This evidence concerns the gene CD33 and acute myeloid leukemia.